Without PCSK9 inhibition, PCSK9 decreases the number of available LDL-Rs on liver cells, resulting in higher LDL-C levels in the bloodstream.1
PCSK9 inhibition with Praluent® increases the number of available LDL-Rs, resulting in lower LDL-C levels in the bloodstream.1
Figure © Sanofi.
This content is down for maintenance
LDL-C=low-density lipoprotein cholesterol; LDL-R=low-density lipoprotein receptor; PCSK9i=proprotein convertase subtilisin/kexin type 9 inhibitor.